

NYRx Notice to Providers: Molluscum Contagiosum and Zelsuvmi

May 14, 2026

NYRx, the Medicaid Pharmacy Program, records indicate there have been claims for Zelsuvmi submitted by your practice for New York State Medicaid members.

What Providers Need to Know

Zelsuvmi is indicated to treat molluscum contagiosum, a benign viral skin condition that **typically resolves on its own**, without treatment. Zelsuvmi is supplied in a carton containing two individual tubes of topical gel that require mixing of equal amounts from each tube prior to administration. **Each 31 g package of Zelsuvmi costs approximately \$2000.**

What Providers Need to Do

When making clinical decisions, it is essential to evaluate the number and location of lesions, potential for irritation from treatment, and the likelihood of spontaneous resolution. Please consider prescribing Zelsuvmi **only** for cases that are not resolving on their own over the expected course of time or if the lesions are in the genital area.

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)
- [NYRx Prior Authorization Submission Guide](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.